The Weill Cornell Graduate School of Medical Sciences honored the Class of 2020 for their academic achievements during a virtual convocation ceremony on May 27. Students and their families and friends watched a livestream of the event, as graduate school faculty announced the recipients of special awards and prizes.
A triple combination of an investigational drug that enables immune cells to infiltrate tumors, an immunotherapy drug and chemotherapy showed promising responses in patients with the most common type of metastatic pancreatic cancer, according to data from an international phase 2a clinical trial led by Weill Cornell Medicine and Beth Israel Deaconness Medical Center investigators.
As the first wave of the COVID-19 pandemic begins to subside in parts of the United States, doctors around the country and especially in hard-hit New York City are reporting cases of an apparently related inflammatory syndrome.
The prospect of residency typically brings jitters to newly minted doctors as they prepare to start the next phase of their medical training, and the level and scope of their patient care responsibilities increases. But the transition has become far more complex with numerous unknowns surrounding the ongoing COVID-19 pandemic.
In March, as the COVID-19 pandemic gained a visible foothold in New York City, Weill Cornell Medicine and NewYork-Presbyterian faced a task unlike any they had encountered before: How would they quickly establish a reliable diagnostic testing program to identify patients and healthcare workers who had been exposed to SARS-CoV-2 amid a rapidly escalating public health crisis?
Dr. Monika Safford, chief of the Division of General Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, finds that obesity is linked to more serious complications from COVID-19, including in younger people.
Higher levels of a type of fungus in the gut are associated with better outcomes for patients with a type of inflammatory bowel disease called ulcerative colitis who are treated with gut microbes from healthy donors.
Neurologists traditionally have expected that patients who remain in coma after cardiac arrest have almost no chance of making a meaningful recovery if they fail to emerge from coma within a week.
As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.
Weill Cornell Medicine–Qatar on May 6 celebrated the dedication and hard work of some of the world’s newest doctors as the Class of 2020 received their Cornell University medical degrees during commencement.
Physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to confront the COVID-19 pandemic, focusing a broad spectrum of expertise on the critical issues the disease is posing to healthcare workers and public health officials.
Although COVID-19 is a threat to everyone, people of color have been hit especially hard by the virus — what has been called a “pandemic within the pandemic.”
A class of immune cells push themselves into an inflammatory state by producing large quantities of a serotonin-making enzyme, according to a study in mice led by scientists at Weill Cornell Medicine.
Growth of the prostate is exceptionally common in aging men, leading to problems with urination. This overgrowth is not a tumor-like condition driven by gene mutations, and may be treatable in many cases with a class of drugs called mTOR inhibitors, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
More than 50 doctors, nurses and other healthcare professionals from Cayuga Health in Ithaca have joined their Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center counterparts to care for New Yorkers diagnosed with COVID-19.
COVID-19almost always starts with relatively mild, flu-likesymptoms that can be treated at home. People who have these symptoms usually do not need to be tested to confirm the infection.
Among the confounding aspects of the novel coronavirus is the wide range of disease severity patients experience. While a minority of COVID-19 patients require hospitalization, the effects of infection for these people are dramatic and in some cases life threatening.
With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.
